曲安奈德/治疗应用

摘要： 目的观察玻璃体腔曲安奈德注射治疗、氪黄激光治疗分支静脉阻塞继发的黄斑水肿的近期疗效和安全性。方法经眼底检查!荧光眼底血管造影!光学相干断层扫描,对23例视网膜分支静脉阻塞继发的严重黄斑水肿患者,患眼行玻璃体腔曲安奈德注射,观察治疗前和治疗后1天、3天、1周、1个月、3个月时分别为:0.57^+0.43/0.57—0.43;0.38^+0.32/0.38—0.32;0.29^+0.29/0.29—0.29。在23眼中,有20眼视力提高,3眼视力不变,23眼中有3眼治疗后暂时性眼压轻度升高,经局部药物短期治疗后恢复正常。所有患眼为出现眼内炎、白内障、视网膜脱离、玻璃体出血等并发症。结果在本次实验视力治疗过程的22名对象中,按照国际标准视力表查验可见有19名对象视力有明显增高占比百分之八十六,同时视力保证不变的有3例,占比百分之十四,所有对象治疗后相比治疗前视力有显著改善,数值差异相较值P<0.01.黄斑中心凹厚度治疗前(519.0-137.5)L逐渐改变为(256.4-68.3)L!(239.4-52.2)L,数值比较P<0.01.患者治疗前后黄斑中心凹阈值黄斑中心凹阈值比较有明显差异性,P<0.01.患者眼底部黄斑水肿有明显减弱,而黄斑区渗漏表现明显。本组22例对象中共有6例病患1治疗后眼压升高治疗(降眼压药物)后未得到控制,注射后3视力下降黄斑水肿控制1例。结论玻璃体腔曲安奈德注射抗炎在短期内安全有效的治疗视网膜分支静脉阻塞继发的黄斑水肿。

摘要： [目的] 比较超声引导下局部注射32P胶体及曲安奈德与无水乙醇治疗甲状腺囊肿临床疗效.[方法] 选取2010年2月至2014年6月广西医科大学第一附属医院收治的甲状腺囊肿患者372例,随机分为观察组和对照组,每组各186例.对照组在超声引导下穿刺注射无水乙醇,观察组在超声引导下注射32P胶体及曲安奈德,比较两组患者临床疗效,并于术后1年进行随访,记录两组患者复发情况.[结果] 观察组:治愈158例(84.9%)、有效23例(12.4%)、无效5例(2.7%),有效率为97.3%(181/186);对照组:治愈139例(74.7%)、有效38例(20.4%)、无效9例(4.9%),有效率为95.1%(177/186).观察组有效率显著高于对照组,经秩和检验差异有统计学意义(P=0.014).术后随访一年,两组治愈及有效患者均无复发病例.[结论] 超声引导下局部注射32P胶体及曲安奈德治疗甲状腺囊肿,具有操作简便、安全、治疗效果好等优点,且创伤小、患者易于接受,可作为甲状腺囊肿的常规治疗方法.%[Objective]To compare the clinical efficacy of local injection of 32P colloid combined with triamcinolone acetonide and the therapy of absolute ethanol in the treatment of thyroid cyst.[Methods]From February 2010 to June 2014, 372 patients with thyroid cyst in our hospital were randomly divided into observation group and control group, each group had a total of 186 cases.The control group underwent percutaneous ethanol injection under ultrasound guided, the observation group underwent injection of triamcinolone acetonide and 32P colloid under ultrasound guided.The clinical efficacy of the two groups were compared, and the patients were followed up for at least 1 year after operation.The recurrence of the two groups were recorded.[Results]In the observation group: 158 cases (84.9%) were cured, effective in 23 cases (12.4%), ineffective in 5 cases (2.7%), the effective rate was 97.3% (181/186);in the control group: i139 cases were cured (74.7%), effective in 38 cases (20.4%), invalid in 9 cases (4.9%), the effective rate was 95.1%(177/186).The effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P=0.014).All patients were followed up for one year.There were no recurrence cases in the two groups.[Conclusion]The therapy of injection of 32P colloid and triamcinolone acetonide under Ultrasound guided for the treatment of thyroid cyst has the advantages of simple operation, safety with good treatment effect to be easily accepted by patients with small wound.It can be used as a routine treatment for thyroid cyst.

摘要： 目的:分析白内障术后黄斑囊样水肿治疗中复方血栓通胶囊联合曲安奈德注射液球旁注射的疗效.方法:以随机数字表法,将60例接受白内障手术治疗后出现黄斑囊样水肿患者分为两组,各30例.对照组接受曲安奈德注射液球旁注射治疗,治疗组接受复方血栓通胶囊联合曲安奈德注射液球旁注射治疗.结果:两组治疗过程中,眼压及视力均呈升高趋势,黄斑区视网膜厚度呈下降趋势(P<0.05),在治疗4周、治疗8周及治疗12周时,治疗组眼压及视力高于对照组,黄斑区视网膜厚度低于对照组(P<0.05).治疗12周后,治疗组总有效率高于对照组(P<0.05),不良反应比较无统计学差异.结论:复方血栓通胶囊联合曲安奈德注射液球旁注射治疗可有效改善白内障术后黄斑囊样水肿的临床效果.

摘要： Objective To observe the short-term efficacy of posterior sub-tenon injection of triamcinolone acetonide (PSTA) in the treatment of macular edema due to ischemic retinal vein occlusions (RVO).Methods A retrospective clinical study.A total of 53 eyes of 53 patients with RVO macular edema diagnosed by fundus color photography,fundus fluorescein angiography and optical coherence tomography (OCT) were included in the study.The best corrected visual acuity (BCVA) was detected by the international standard visual acuity chart,and the results were converted to the logarithm of the minimum angle of resolution (logMAR) visual acuity.The central macular thickness (CMT) was measured by OCT.Among 53 eyes,there were 27 eyes with ischemic RVO maeular edema (ischemic group) and 26 eyes with non-ischemic RVO macular edema (non-ischemic group).The mean logMAR BCVA was 0.82±0.37,mean CMT was (662.1±216.7) μm in ischemic group.The mean logMAR BCVA was 0.41±0.23,mean CMT was (548.0± 161.9) μm.The differences of logMAR BCVA and CMT between the two groups werw both statistically significant (t =4.745,2.258;P＜ 0.05).All eyes were treated with a single sub-Tenon injection of 0.4 ml triamcinolone acetonide suspension (100 mg/ml).The mean logMAR BCVA,CMT before and 1,3 months after the treatment between the two groups were observed and compared.Results On 1 and 3 months after treatment,the mean logMAR BCVA in the non-ischemic group (0.32±0.25 and 0.27±0.29) were improved compared with ischemic group (0.76±0.37 and 0.41±0.79),the difference was statistically significant (t=5.052,5.240;P＜0.05).The mean logMAR BCVA before and after treatment had no statistically significant difference in ischemic group (F=0.516,P＞0.05),but had a statistically significant difference in non-ischemic group (F=7.685,P＜0.05).On 1 and 3 months after treatment,the mean CMT in the ischemic group were (534.7±223.4),(470.8±234.7) μm,which were lower (127.4 ± 28.28),(191.4 ± 34.55) μm before treatment.In the non-ischemic group,the average CMT was (426.2±188.8),(371.3±200.6) μm,which were lower (103.1±33.1),(164.9±49.6) μm.There were statistically significant differences in the mean CMT between the ischemic group and the non ischemic group (F=17.040,10.360;P＜0.05).In non-ischemic group,CMT had a bigger reduction compared to the the ischemic group (t=2.056,2.103;P＜0.05).The difference of CMT decrease value between two groups was not statistically significant (t=0.560,0.441;P＞0.05).On 1 month after the treatment,there were 3 and 5 eyes had a higher intraocular pressure than 21 mmHg (1 mmHg=0.133 kPa) in ischemic and non-ischemic group,respectively;but all of them returned to normal after drug treatment.There were no drugs and ocular injection related complications.Conclusion PSTA of ischemic RVO macular edema can lower the CMT in the short term,but can't significant improve the visual acuity.%目的 观察后Tenon囊下注射曲安奈德(PSTA)治疗缺血型视网膜静脉阻塞(RVO)黄斑水肿的短期临床疗效.方法 回顾性非随机对照临床研究.通过眼底彩色照相、荧光素眼底血管造影及光相干断层扫描(OCT)检查确诊的RVO黄斑水肿患者53例53只眼纳入研究.所有患眼均采用国际标准视力表检测最佳矫正视力(BCVA),并将结果转换为最小分辨角对数(logMAR)视力记录.利用OCT自带软件测量患眼黄斑中心凹厚度(CMT).53只眼中,缺血型RVO黄斑水肿(缺血型组)27只眼,平均logMARBCVA为0.82±0.37,平均CMT为(662.1±216.7) μm;非缺血型RVO黄斑水肿(非缺血型组)26只眼,平均logMAR BCVA为0.41±0.23,平均CMT为(548.0±161.9) μm.两组患眼logMAR BCVA、CMT比较,差异有统计学意义(t=4.745、2.258,P＜0.05).所有患眼均行单次PSTA治疗,注射曲安奈德悬浮液0.4 ml(含曲安奈德40 mg).对比观察两组患眼治疗后1、3个月logMAR BCVA、CMT与治疗前logMAR BCVA、CMT的异同以及药物、眼部注射相关并发症的发生情况.结果 治疗后1、3个月,缺血型组患眼平均logMAR BCVA分别为0.76±0.37、0.79±0.41;非缺血型组患眼平均logMAR BCVA分别为0.32±0.25、0.27±0.29.非缺血型组患眼平均logMAR BCVA较缺血型组患眼明显提高,差异有统计学意义(t=5.052、5.240,P＜0.05).缺血型组患眼治疗前后平均logMAR BCVA比较,差异无统计学意义(F=0.516,P＞0.05);非缺血型组患眼治疗前后平均logMAR BCVA比较,差异有统计学意义(F=7.685,P＜0.05).治疗后1、3个月,缺血型组患眼平均CMT分别为(534.7±223.4)、(470.8±234.7) μm,较治疗前分别降低(127.4±28.3)、(191.4±34.6) μm.非缺血型组患眼平均CMT分别为(426.2±188.8)、(371.3±200.6)tm,较治疗前分别降低(103.1±33.1)、(164.9±49.6) μm.非缺血型组患眼平均CMT较缺血型组患眼低,差异有统计学意义(t=2.056、2.103,P＜0.05);两组患眼之间平均CMT降低值比较,差异均无统计学意义(t=0.560、0.441,P＞0.05).缺血型组、非缺血型组患眼治疗前后平均CMT比较,差异均有统计学意义(F=17.040、10.360,P＜0.05).治疗后1个月时,缺血型组、非缺血型组分别有3、5只眼眼压＞21 mmHg(1 mmHg=0.133 kPa),通过降眼压药物治疗后均恢复正常.所有患眼均未出现眼球破裂、球后出血、上睑下垂和眶蜂窝织炎等与药物、眼部注射相关的并发症.结论 PSTA治疗缺血型RVO黄斑水肿短期内可降低患眼CMT,但对视力无明显改善作用.

摘要： 目的：探讨氟尿嘧啶联合曲安奈德治疗瘢痕疙瘩的疗效。方法：将92例瘢痕疙瘩患者随机分为观察组和对照组，每组各46例。对照组患者接受曲安奈德治疗，观察组患者接受氟尿嘧啶配伍曲安奈德治疗。对比两组患者治疗效果及不良反应发生率。结果：观察组总有效率为97．83％，明显高于对照组的82．61％（ P＜0．05）；毛细血管扩张、皮损周围正常皮肤萎缩、色素改变、食欲下降、月经不调等并发症发生率为13．04％，明显低于对照组的32．61％（ P＜0．05）。结论：瘢痕疙瘩患者接受氟尿嘧啶配伍曲安奈德有助于提高治疗效果，减少不良反应发生率。

摘要： 目的：探讨弹力压迫硅胶喷剂外喷及局部曲安奈德注射防治烧伤后瘢痕形成的疗效。方法：将102例烧伤患者（845处烧伤部位）随机分为对照组和试验组。对照组给予弹力压迫硅胶喷剂外喷治疗，试验组加施局部曲安奈德注射治疗，比较两组烧伤部位治疗效果评价、瘢痕厚度与胶原纤维面密度、TGF‐β阳性细胞与α‐SM actin阳性细胞密度。结果：试验组烧伤部位治疗总有效率显著性高于对照组，差异具有统计学意义；试验组烧伤部位瘢痕厚度与胶原纤维面密度组间比较显著性低于对照组，差异具有统计学意义；试验组烧伤部位 TGF‐β阳性细胞与α‐SM actin阳性细胞密度组间比较显著性低于对照组，差异具有统计学意义。结论：弹力压迫硅胶喷剂外喷及局部曲安奈德注射防治烧伤后瘢痕形成的疗效显著。

摘要： 目的：观察激光联合玻璃体腔注射小剂量曲安奈德（TA）治疗视网膜分支静脉阻塞（BRVO）合并黄斑水肿（ME）的疗效和安全性。方法：据荧光素眼底血管造影（FFA）对BRVO合并ME患者38例38眼随机分为两组：对照组（17眼）单纯行黄斑区格栅样光凝，治疗组（21眼）玻璃体腔注射1次TA0．05ml（2mg），1～2周后行黄斑区格栅样光凝；随访3个月，观察最佳矫正视力及光学相干断层扫描（OCT）检查黄斑中央厚度。结果：治疗组临床疗效总有效率95．2％，对照组总有效率64．7％，治疗组总有效率显著高于对照组，差异有统计学意义。观察期间未发生眼压升高、并发性白内障、玻璃体出血、眼内炎等并发症。结论：激光联合玻璃体腔注射小剂量曲安奈德治疗视网膜分支静脉阻塞合并黄斑水肿，是一种安全、有效、经济的治疗方法。

摘要： 目的：探讨口腔扁平苔藓患者采用醋酸泼尼松龙联合曲安奈德治疗的临床疗效。方法：按随机数字表法将110例口腔扁平苔藓患者分为对照组与观察组，每组55例。对照组单纯采用曲安奈德注射液治疗，观察组采用醋酸泼尼松龙联合曲安奈德治疗，比较两组患者的治疗效果。结果：经治疗后，观察组痊愈18例，显效19例，有效15例，无效3例，治疗总有效率为94．55％（52／55）；对照组痊愈12例，显效16例，有效14例，无效13例，治疗总有效率为76．36％（42／55）。观察组患者治疗效果明显好于对照组（P＜0．05）。结论：采用醋酸泼尼松龙联合曲安奈德治疗口腔扁平苔藓可有效缓解患者的临床症状，改善其生活质量，疗效确切。

摘要： 目的 观察白内障超声乳化手术中联合玻璃体腔注射曲安奈德(IVTA)治疗糖尿病黄斑水肿(DME)合并重度白内障的临床效果.方法 临床检查确诊为DME伴重度白内障患者21例25只眼纳入研究.其中,15只眼行标准白内障超声乳化联合人工晶状体植入手术及IVTA治疗(IVTA组),10只跟仅行标准白内障超声乳化联合人工晶状体植入手术(非IVTA组).所有患眼均行最佳矫正视力(BCVA)、裂隙灯显微镜、间接检眼镜及光相干断层扫描(OCT)检查.采用重复测量方差分析,对比IVTA组、菲 IVTA组手术后1、3、6个月的平均最小分辨角对数(logMAR) BCVA及黄斑中心凹厚度(CMT)变化情况.对手术前后logMAR BCVA与CMT行Pearson相关性分析.采用多元线性回归分析法分析影响手术后6个月视力恢复的相关因素.结果 重复测量方差分析结果显示,IVTA组与非IVTA组手术后平均logMAR BCVA均较手术前提高.IVTA组与非IVTA组手术前后平均logMAR BCVA比较,差异有统计学意义(F=4.855、6.235,P=0.037、0.020).手术后1、3、6个月,IVTA组与非IVTA组平均logMARBCVA改善程度比较,差异均无统计学意义(F=0.007、0.006、0.023,P=0.973、0.938、0.882).手术后1、3个月,IVTA组CMT降低程度优于非IVTA组;两组CMT降低程度比较,差异有统计学意义(F=10.449、7.374,P=0.012、0.026).手术后6个月,IVTA组与非IVTA组CMT降低程度比较,差异无统计学意义(F=2.173,P=0.114).相关性分析结果显示,手术前及手术后6个月平均logMAR BCVA与平均CMT之间均无相关性(r=0.279、0.172,P=0.295、0.574).多元线性回归分析结果显示,影响手术后6个月视力恢复的因素有外界膜状态和糖尿病病程(β=0.577、-0.411,P=0.025、0.030).结论 白内障超声乳化手术中联合IVTA治疗DME合并重度白内障可在短期内减轻黄斑水肿,改善患者视力.%Objective To observe the efficacy of phacoemulsification with intravitreal triamcinolone injection (IVTA) in diabetic patients with severe cataract and diabetic macular edema (DME).Methods Twenty-one patients (25 eyes) with severe cataract and DME were enrolled in this retrospective study.Fifteen eyes underwent standard phacoemulsification and intraocular lens implantation with 4 mg IVTA at completion of surgery.Ten eyes underwent standard phacoemulsification and intraocular lens implantation.All the patients were followed up for best corrected visual acuity (BCVA),optical coherence tomography (OCT) and ophthalmological examination.Changes in logarithm of he minimal angel of resolution (logMAR) BCVA and central macular thickness (CMT) were evaluated preoperatively and 1 month,3 months and 6 months postoperatively by repeated measures ANOVA.Correlations between logMAR BCVA and CMT preoperatively and postoperatively were analyzed by Pearson correlation analysis.Postoperative 6 months logMAR BCVA and affecting factors were evaluated by multivariate linear regression analysis.Results Both groups showed significant improvements of logMAR BCVA after surgery (F=4.855,6.235; P=0.037,0.020).There were no statistical differences of logMAR BCVA improvement at different time points postoperatively (F=0.007,0.006,0.023; P=0.973,0.938,0.882).The CMT reductions in IVTA group at month 1 and month 3 postoperatively were statistically significant than the reductions in group without IVTA(F=10.449,7.374; P=0.012,0.026),and there was no statistical difference of CMT reduction at month 6 postoperatively between two groups (F =2.173; P =0.114).Correlation Coefficients between CMT and BCVA were not statistically significant preoperatively and 6 months postoperatively(r=0.279,0.172; P=0.295,0.574).Analysis of multiple linear regression showed that external limiting membrane status and duration of diabetes are factors affecting the visual recovery (β=0.577,-0.411; P=0.025,0.030).Conclusions Phacoemulsification with concurrent IVTA for treatment of patients with severe cataract and DME is effective in reducing edema.But IVTA does not further improve logMAR BCVA postoperatively.

摘要： Objective To observe the expression of inflammatory cytokines in diabetic rats received posterior sub-Tenon capsule injection of triamcinolone acetonide (TA) and pan-retinal photocoagulation.Methods A total of 48 Brown Norway rats received intraperitoneal injection of streptozotocin to establish the diabetic model.Diabetic rats were randomly divided into experimental group (20 rats),control group (20 rats) and blank group (8 rats).50 μl TA or saline was injected into the posterior sub-Tenon capsule immediately after the photocoagulation in the experimental group and the control group,respectively.The blank group received no treatment.The mRNA and protein expression level of retinal vascular endothelial growth factor (VEGF),interleukin 6 (IL-6) and tumor necrosis fator-α (TNF-α) were measured by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA) at 1,3,7 days after laser photocoagulation.Results The mRNA and protein expression of VEGF,IL-6,TNF-α of the experimental group and control group were significantly higher than the blank group,the difference was statistically significant (P＜0.05).The mRNA and protein expression of VEGF,IL-6 and TNF-α of the experimental group were significantly lower than that of the control group.On day 1 after laser photocoagulation,the mRNA expression of VEGF was not statistically significant in the experimental group and control group (P＞0.05),the mRNA and protein expression of VEGF,IL-6,TNF-α of the two groups were statistically significant in the remaining observing time (P＜0.05).Conclusion Posterior sub-Tenon capsule injection of TA can effectively reduce retinal photocoagulation induced VEGF,IL-6,TNF-α expression.%目的 观察后Tenon囊下注射曲安奈德(TA)对激光光凝后糖尿病大鼠视网膜炎症相关细胞因子表达的影响.方法 雄性Brown Norway健康大鼠48只,通过腹腔注射链脲佐菌素建立糖尿病大鼠模型.将大鼠随机分成实验组、对照组和空白组,分别为20、20、8只大鼠.实验组、对照组大鼠行激光光凝后,给予后Tenon囊下注射TA或生理盐水50μl.空白组不作任何处理.激光光凝后1、3、7d,采用荧光定量聚合酶链反应和酶联免疫吸附试验检测大鼠视网膜中血管内皮生长因子(VEGF)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的mRNA和蛋白表达.结果 激光光凝后1、3、7d,实验组和对照组分别与空白组比较,其VEGF、IL-6、TNF-α mRNA和蛋白表达均明显升高,差异均有统计学意义(P＜0.05).实验组VEGF、IL-6、TNF-α mRNA和蛋白表达均较对照组明显下降.实验组与对照组比较,激光光凝后1d,VEGF mRNA表达间差异无统计学意义(P＞0.05);其余各时间点VEGF、IL-6、TNF-α mRNA和蛋白表达间差异均有统计学意义(P＜0.05).结论 后Tenon囊下注射TA可有效降低激光光凝导致的糖尿病大鼠VEGF、IL-6、TNF-α表达水平的升高.

摘要： 本发明提供了组合物及使用所述组合物的方法，用于注射至人或动物眼部的后节。所述组合物包括溶解性较差的治疗剂的小颗粒，所述颗粒促进治疗剂在眼部视网膜色素上皮形成较浓的治疗剂区域。所述颗粒通过将治疗剂与眼用聚合物成分结合而形成。所述颗粒的尺寸小于约3000纳米，并且在某些情况下，小于约200纳米。组合物的一个实例包括尺寸小于约3000纳米的曲安奈德及透明质酸的颗粒。

摘要： 本发明提供一种负载曲安奈德水凝胶复合物的制备方法及应用，所制备复合物解决了水凝胶低载药量和高溶胀性的缺点，可以成功抑制小鼠角膜新生血管生成。本发明所提供的整体材料在生物医学领域的药物控释方面具有广泛的应用前景；而选用不同浓度的药物和药物浸泡时间还可以控制缓释的效果，以更好的应用于临床。

摘要： 本发明提供了一种曲安奈德PLGA缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用，所述制剂包含曲安奈德、PLGA共聚物和玻尿酸，其中，PLGA与曲安奈德的重量比为100:(5～25)；PLGA与玻尿酸的重量比为100:(5～15)。本发明的载药缓释微球具有较好的稳定性。采用PLGA微球包载曲安奈德，不仅可以缓慢释放药物，同时可以增加药物稳定性，减少药物水解。反相疏水高效液相法检测结果显示，体外释放于水溶液的速释曲安奈德有明显的降解吸收峰，而包载在微球内的曲安奈德结构较完整，无明显降解产物吸收峰出现。玻尿酸同时起到协同增效作用，因为玻尿酸改善膝关节粘度，进一步减小曲安奈德的清除率，延长作用时间。

摘要： 用于治疗鼻部炎症的含有醋酸曲安奈德和NOS抑制剂的药物组合物，含有作为活性成分的醋酸曲安奈德和作为NOS抑制剂的氨基酸衍生物，以及一种或多种适用于鼻部给药的药物辅料和余量的水。

摘要： 本发明提供了一种应用含曲安奈德的局部用制剂对治疗宫颈糜烂进行治疗或预防的方法。这种制剂可以是曲安奈德和其他辅料，或曲安奈德与一种或多种抗生素的组合。本发明的治疗方法可以采用含曲安奈德的各种局部用剂型，如阴道乳膏剂，阴道凝胶剂，阴道栓剂，阴道泡腾片剂，阴道片剂，阴道油膏剂等。本发明的治疗方法所采用的制剂具有抗炎和血管收缩功能，对糜烂面积缩小、变浅和消失起有效作用，并对抑制宫颈糜烂的复发有效。

摘要： 本发明提供了组合物及使用所述组合物的方法，用于注射至人或动物眼部的后节。所述组合物包括溶解性较差的治疗剂的小颗粒，所述颗粒促进治疗剂在眼部视网膜色素上皮形成较浓的治疗剂区域。所述颗粒通过将治疗剂与眼用聚合物成分结合而形成。所述颗粒的尺寸小于约3000纳米，并且在某些情况下，小于约200纳米。组合物的一个实例包括尺寸小于约3000纳米的曲安奈德及透明质酸的颗粒。

摘要： 一株曲安奈德单克隆抗体杂交瘤细胞株及其应用，属于食品安全免疫检测领域。本发明分泌曲安奈德单克隆抗体杂交瘤细胞株STD 6B11，分类命名为单克隆细胞株，保藏日期2020年9月27日，保藏编号CGMCC No.20783。此细胞株分泌的单克隆抗体，对曲安奈德具有较好的特异性和检测灵敏度。本发明合成了曲安奈德半抗原，制备了曲安奈德完全抗原，并将它与等量弗氏佐剂混合乳化完全，通过背部皮下注射免疫BALB/c小鼠，经过间接竞争酶联免疫法的筛选和三次亚克隆，得到杂交瘤细胞株STD 6B11。此细胞株分泌的单克隆抗体，对曲安奈德具有较好的特异性和检测灵敏度(IC50为0.49ng/mL)。本发明成果可用于建立猪肉和其他含有曲安奈德的食品中曲安奈德含量的免疫检测方法，具有实际应用价值。

摘要： 本发明提供一种负载曲安奈德水凝胶复合物的制备方法及应用，所制备复合物解决了水凝胶低载药量和高溶胀性的缺点，可以成功抑制小鼠角膜新生血管生成。本发明所提供的整体材料在生物医学领域的药物控释方面具有广泛的应用前景；而选用不同浓度的药物和药物浸泡时间还可以控制缓释的效果，以更好的应用于临床。

摘要： 本发明提供了生物蛋白胶‑曲安奈德缓释剂及其制备方法和用途，缓释剂包含生物蛋白胶、抑肽酶、曲安奈德，其中生物蛋白胶用作药物载体，抑肽酶用作缓溶剂，曲安奈德用作有效药物成分。制备得到的生物蛋白胶‑曲安奈德缓释剂通过内镜直接喷涂在消化道相应手术区域处，能发挥持久抗炎作用，减少术后瘢痕形成，预防术后食管狭窄，有效改善患者生活质量。

摘要： 本实用新型公开了一种治疗食管良性狭窄全覆膜曲安奈德涂层的食管支架，该治疗食管良性狭窄全覆膜曲安奈德涂层的食管支架包括：曲安奈德涂层、带膜支架、金属丝、柔性材料膜、减张环、弹性环、防返流瓣。本实用新型通过设置曲安奈德涂层和带线覆膜支架，使狭窄部位得到有效扩张，同时有效阻止胶原的生成，减轻了对组织的刺激。本实用新型有效的避免了金属丝对腔管的刺激和因腔管的蠕动导致带膜支架端部的肉芽增生形成的再狭窄，特别适合于良性狭窄的治疗。此外，本实用新型结构简单，操作方便，制作成本低，提供了一种性能优良的治疗食管良性狭窄全覆膜曲安奈德涂层的食管支架。